Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amir Hossein Miri, Mojtaba Kamankesh, Mazda Rad-Malekshahi, Abbas Yadegar, Maryam Banar, Michael R. Hamblin, Ismaeil Haririan, Hamid Asadzadeh Aghdaei & Mohammad Reza Zali. (2023) Factors associated with treatment failure, and possible applications of probiotic bacteria in the arsenal against Helicobacter pylori. Expert Review of Anti-infective Therapy 21:6, pages 617-639.
Read now
Read now
Marta Narczyk, Marta Ilona Wojtyś, Ivana Leščić Ašler, Biserka Žinić, Marija Luić, Elżbieta Katarzyna Jagusztyn-Krynicka, Zoran Štefanić & Agnieszka Bzowska. (2022) Interactions of 2,6-substituted purines with purine nucleoside phosphorylase from Helicobacter pylori in solution and in the crystal, and the effects of these compounds on cell cultures of this bacterium. Journal of Enzyme Inhibition and Medicinal Chemistry 37:1, pages 1083-1097.
Read now
Read now
Inès Ben Ghezala, Maxime Luu & Marc Bardou. (2022) An update on drug–drug interactions associated with proton pump inhibitors. Expert Opinion on Drug Metabolism & Toxicology 18:5, pages 337-346.
Read now
Read now
Cláudia Sousa, Rute Ferreira, Nuno F. Azevedo, Mónica Oleastro, Joana Azeredo, Ceu Figueiredo & Luís D. R. Melo. (2022) Helicobacter pylori infection: from standard to alternative treatment strategies. Critical Reviews in Microbiology 48:3, pages 376-396.
Read now
Read now
Elias Xirouchakis & Sotirios D. Georgopoulos. (2022) Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opinion on Pharmacotherapy 23:2, pages 201-210.
Read now
Read now
Articles from other publishers (18)
Mengqiu Xiong, Hend Sadeq Mohammed Aljaberi, Nida Khalid Ansari, Yalan Sun, Sijie Yin, Lubanga Nasifu, Huiling Sun, Tao Xu, Yuqin Pan, Zhenlin Nie, Caidong Liu, Zhenyu Zhang, Zongdan Jiang, Shukui Wang & Bangshun He. (2023)
Phenotype and genotype analysis for
Helicobacter pylori
antibiotic resistance in outpatients: a retrospective study
. Microbiology Spectrum 11:5.
Crossref
Crossref
Tjeerd Pieter van Staa, Munir Pirmohamed, Anita Sharma, Darren M. Ashcroft & Iain Buchan. (2023) Adverse drug reactions and hospital admissions: Large case‐control study of patients aged 65–100 years using linked English primary care and hospital data. Pharmacoepidemiology and Drug Safety.
Crossref
Crossref
Rafał Frański & Monika Beszterda-Buszczak. (2023) Comment on Villalva et al. Antioxidant, Anti-Inflammatory, and Antibacterial Properties of an Achillea millefolium L. Extract and Its Fractions Obtained by Supercritical Anti-Solvent Fractionation against Helicobacter pylori. Antioxidants 2022, 11, 1849. Antioxidants 12:6, pages 1226.
Crossref
Crossref
Nataliya V. Yakovleva, Galina I. Smirnova & Anatoliy A. Korsunsky. (2023) Modern aspects of Helicobacter pylori infection. Russian Pediatric Journal 26:1, pages 67-74.
Crossref
Crossref
Sumaira Khadim, Iyad Muhammad Naeem, Muhammad Tanveer Alam, Hina Rehman, Sidra Ghayas & Sajjad Haider. (2023) The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials. Archives of Medical Science – Civilization Diseases 8:1, pages 31-37.
Crossref
Crossref
Ante Bubić, Marta Narczyk, Ana Petek, Marta Ilona Wojtyś, Weronika Maksymiuk, Beata Wielgus-Kutrowska, Maria Winiewska-Szajewska, Tea Pavkov-Keller, Branimir Bertoša, Zoran Štefanić, Marija Luić, Agnieszka Bzowska & Ivana Leščić Ašler. (2023) The pursuit of new alternative ways to eradicate Helicobacter pylori continues: Detailed characterization of interactions in the adenylosuccinate synthetase active site. International Journal of Biological Macromolecules 226, pages 37-50.
Crossref
Crossref
Shu-Peng Zou, Qian Cheng, Cheng-Yang Feng, Chan Xu & Ming-Hui Sun. (2022)
Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant
Helicobacter pylori
strains: A network meta-analysis
. World Journal of Clinical Cases 10:35, pages 12959-12970.
Crossref
Crossref
Vladimir I. Simanenkov & Sergei A. Alekseenko. (2022) Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra. Terapevticheskii arkhiv 94:8, pages 935-939.
Crossref
Crossref
Malek Shatila & Anusha Shirwaikar Thomas. (2022) Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. Journal of Clinical Medicine 11:17, pages 5086.
Crossref
Crossref
Naomi Gronich, Idit lavi, Flavio Lejbkowicz, Mila Pinchev & Gad Rennert. (2022) Association of CYP2C19 Polymorphism With Proton Pump Inhibitors Effectiveness and With Fractures in Real‐Life: Retrospective Cohort Study. Clinical Pharmacology & Therapeutics 111:5, pages 1084-1092.
Crossref
Crossref
G. V. Osyodlo, O. V. Tsyts, S. M. Prokopchuk, Y. Y. Kotyk & V. V. Osyodlo. (2022) Ерозивно-виразкові захворювання гастродуоденальної зони у військовослужбовців: клінічні та фармакоекономічні аспекти. Ukrainian Journal of Military Medicine 3:1, pages 51-59.
Crossref
Crossref
Nikos Viazis, Konstantinos Argyriou, Katerina Kotzampassi, Dimitrios K. Christodoulou, Periklis Apostolopoulos, Sotirios D. Georgopoulos, Christos Liatsos, Olga Giouleme, Kanellos Koustenis, Christos Veretanos, Dimitris Stogiannou, Miltiadis Moutzoukis, Charalambos Poutakidis, Ioannis Ioardanis Mylonas, Ioulia Tseti & Gerassimos J. Mantzaris. (2022) A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients 14:3, pages 632.
Crossref
Crossref
Jia Jia, Chongwen Zhang, Yaqi Liu, Yanqiang Huang, Yuefan Bai, Xudong Hang, Liping Zeng, Dongqing Zhu & Hongkai Bi. (2021)
Armeniaspirol A: a novel anti‐
Helicobacter pylori
agent
. Microbial Biotechnology 15:2, pages 442-454.
Crossref
Crossref
Zheyu Wang & Fen Wang. (2022)
Efficacy and safety comparison of
Helicobacter pylori
eradication between vonoprazan dual therapy
versus
triple therapy: a systematic review and meta-analysis
. Therapeutic Advances in Gastroenterology 15, pages 175628482211253.
Crossref
Crossref
Paweł Krzyżek, Adam Junka, Wojciech Słupski, Arleta Dołowacka-Jóźwiak, Bartosz J. Płachno, Aleksandra Sobiecka, Adam Matkowski, Grzegorz Chodaczek, Tadeusz Płusa, Grażyna Gościniak & Sylwia Zielińska. (2021) Antibiofilm and Antimicrobial-Enhancing Activity of Chelidonium majus and Corydalis cheilanthifolia Extracts against Multidrug-Resistant Helicobacter pylori. Pathogens 10:8, pages 1033.
Crossref
Crossref
María Caldas, Ángeles Pérez-Aisa, Bojan Tepes, Alma Keco-Huerga, Luis Bujanda, Alfredo Lucendo, Luis Rodrigo, Dino Vaira, Luis Fernández-Salazar, Jose Huguet, Jorge Pérez-Lasala, Natasa Jurecic, Galina Fadeenko, Jesús Barrio, Miguel Areia, Juan Ortuño, Rinaldo Pellicano, Marcis Leja, Javier Molina-Infante, Pavel Bogomolov, Sergey Alekseenko, Manuel Domínguez-Cajal, Judith Gómez-Camarero, Vassiliki Ntouli, Samuel Martínez-Domínguez, Rafael Ruiz-Zorrilla, Oscar Núñez, Aiman Sarsenbaeva, Pedro Almela, Perminder Phull, Marta Espada, Ignasi Puig, Olga Nyssen, Francis Mégraud, Colm O’Morain, Javier Gisbert & on behalf of the Hp-EuReg Investigators. (2021) The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). Antibiotics 10:8, pages 965.
Crossref
Crossref
Ascensión Rueda-Robles, Teresa Rubio-Tomás, Julio Plaza-Diaz & Ana I. Álvarez-Mercado. (2021) Impact of Dietary Patterns on H. pylori Infection and the Modulation of Microbiota to Counteract Its Effect. A Narrative Review. Pathogens 10:7, pages 875.
Crossref
Crossref
Gracia M. Martin-Nuñez, Isabel Cornejo-Pareja, Mercedes Clemente-Postigo & Francisco J. Tinahones. (2021) Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders?. Frontiers in Endocrinology 12.
Crossref
Crossref